Stay updated on PRS-343 HER2+ Solid Tumors Clinical Trial

Sign up to get notified when there's something new on the PRS-343 HER2+ Solid Tumors Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the PRS-343 HER2+ Solid Tumors Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    7 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a potential update in the dosing schedule of PRS-343 in patients with HER2+ advanced or metastatic solid tumors. This change may impact the evaluation of safety, pharmacokinetics, and pharmacodynamics data for different dosing schedules in the clinical trial.
    Difference
    0.1%
    Check dated 2024-06-06T14:40:08.000Z thumbnail image
  7. Check
    22 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for study participants, specifying requirements such as informed consent, age, health conditions, and prior treatments. Previously, no information was provided in this section.
    Difference
    45%
    Check dated 2024-05-22T21:21:52.000Z thumbnail image
  8. Check
    44 days ago
    Change Detected
    Difference
    0.8%
    Check dated 2024-04-30T22:29:19.000Z thumbnail image

Stay in the know with updates to PRS-343 HER2+ Solid Tumors Clinical Trial

Enter your email address, and we'll notify you when there's something new on the PRS-343 HER2+ Solid Tumors Clinical Trial page.